Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

Abstract

Identification of risk factors for AKI post-CRS-HIPEC helps improve pre-operative patient selection and optimisation, facilitate tailoring of chemotherapy, and foster closer peri-operative monitoring and fluid management in at-risk patients.

Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study

“…Furthermore, obese patients exhibit a higher risk of AKI because of hyperfiltration, increased glomerular capillary wall tension and podocyte stress [25]. Blood transfusions are associated with postoperative AKI in HIPEC surgery [26]. Our study found that the rate of postoperative blood transfusions was higher in patients with AKI.…”

Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

“…In the past decades, several studies have demonstrated an association between ARI after HIPEC and cisplatin-based regimens. A study reported an incidence of overall renal toxicity of 40.4% and an incidence of grade 3-4 renal impairment of 10.6% in ovarian cancer patients treated with cisplatin-based HIPEC regimens according to the criteria of National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.3.0 [4]. Another study reported that 11.1% (11/99) of patients who received HIPEC had a significantly higher risk of ARI and that 10 of these 11 patients received a regimen containing cisplatin (60 mg/m 2 infused for 60-90 min) [5].…”

Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC

“…In another study, AKI occurred in 40.4% of ovarian cancer patients undergoing CRS and HIPEC. All those patients received cisplatin [ 11 ]. More recently, Cata et al reported a 21.3% incidence of AKI.…”

“…To date, only a handful of studies evaluated the incidence of AKI in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal therapy (CRS and HIPEC) [ [9] , [10] , [11] ]. However, kidney injury related to cisplatin, a known nephrotoxic agent, was a major contributor to the occurrence of AKI.…”